MAP2K7 and prostate cancer: The activation of the RAF/RAS/ERK pathway is essential for the inhibition of cell viability of prostate cells by GT3. To determine whether the observed activation of the ERK MAPK pathway is relevant to the effect on cell viability of prostate cancer cells by GT3, we used the MEK inhibitor U0126.